Lung cancer is the second most common cancer in the world, with an estimated 1.8 million deaths each year. In Hong Kong, it is the number one killer among all cancer types, with more than 4,000 new cases recorded every year.
Professor Tony Mok Shu-kam of the Faculty of Medicine, of The Chinese University of Hong Kong (CUHK), worked recently with an international team of lung cancer experts on a phase 3 clinical trial for advanced non-small cell lung cancer with “anaplastic lymphoma kinase (ALK) gene mutation.” The results were promising and showed that this third-generation ALK inhibitor “Lorlatinib” has the potential to become a first-line treatment option regardless of whether the patient has brain metastases.
